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Researchindicatesthatthequalityoftheadherenceassessmentisoneofthebestpredictorsforimprovingclinicaloutcomes.Newer
technologies represent an opportunity for developing high quality standardized assessments to assess clinical outcomes such as
patientexperienceofcarebuthavenotbeentestedsystematicallyinpediatricsicklecelldisease(SCD).Thegoalofthecurrentstudy
was to pilot an interactive web-based tool, the Take-Charge Program, to assess adherence to clinic visits and hydroxyurea (HU),
barriers to adherence, solutions to overcome these barriers, and clinical outcomes in 43 patients with SCD age 6–21 years. Results
indicate that the web-based tool was successfully integrated into the clinical setting while maintaining high patient satisfaction
(>90%). The tool provided data consistent with the medical record, staﬀ report, and/or clinical lab data. Participants reported
that forgetting and transportation were major barriers for adherence to both clinic attendance and HU. A greater number of self-
reported barriers (P<. 01) and older age (P<. 05) were associated with poorer clinic attendance and HU adherence. In summary,
the tool represents an innovative approach to integrate newer technology to assess adherence and clinical outcomes for pediatric
patients with SCD.
1.Introduction
Sickle cell disease (SCD) is a genetic red blood cell disorder
characterized by the sickling of red blood cells resulting
in pain episodes, organ damage, risk for infections, and
decreased life expectancy [1] .C a r eg u i d e l i n e sf o rS C Dr e c -
ommend that patients attend routine clinic appointments
one to two times per year and more frequently if there are
complications or if clinical monitoring is needed to assess
tolerance to medications and other treatments [1, 2]. Pre-
ventative care such as ﬂu shots, immunizations, and moni-
toring labs is also essential to eﬀectively manage sickle cell
disease [3]. Hydroxyurea (HU), which is used to increase
fetal hemoglobin (Hb F), has been shown to decrease
morbidity and mortality in patients with SCD [4]. Studies
have indicated that daily oral HU use is associated with
reduced pain crises, hospitalizations, acute chest syndrome,
and transfusions and improved growth and health-related
qualityoflife[5–9].Thus,theconsequencesofnonadherence
to clinic attendance and HU treatments result in increased
morbidity [10], healthcare costs [11], and decreased quality
of life [12].
There is limited research available examining treatment
nonadherence in pediatric SCD. A meta-analytic review
foundanonadherencerateforclinicappointmentsinpediat-
ricpopulationsofapproximately40%[13].Similarly,nonad-
herence rates for clinic appointments in SCD range between
36%–44% [14, 15]. On the surface, it would seem that
patients who attend their appointments would demonstrate
higher levels of adherence to their treatment regimen;
however, the relationship between clinic attendance and2 Anemia
treatment adherence appears to be complex. As an example,
Finney et al. [16] found that the 48% of patients who kept
their follow-up appointment had been nonadherent to their
prescribed regimen. Thus, it is important to assess barriers
to the treatment regimen even with patients who attend
appointments regularly.
Research on medication adherence in SCD suggests
higher rates for acute medications than daily medications.
Dampier et al. [17] found that 85% of adolescents with SCD
took analgesic medications on days when they experienced
sickle-cell related pain. In contrast, studies found that 38%–
60% of pediatric and adult patients were adherent to their
prescribed days of home chelation therapy or deferoxamine
usage [18, 19] and rates ranged from 12%–67% for young
children with SCD taking prophylactic penicillin [20–22].
Studies of HU adherence in SCD have typically utilized
small sample sizes or single measures of adherence (e.g., pill
counts) [23]. Overall, these studies indicate variable rates of
adherence and lower rates for long-term trials [23, 24]. For
example, Zimmerman and colleagues discontinued HU in
12% of their participants due to nonadherence [24]. Data
from our own clinic indicate that 30% of patients who
wereprescribedHUwerediscontinuedduetononadherence.
PooradherencewithHUmayhaveunintendedconsequences
as the medication can be discontinued on the assumption
that the patient is a nonresponder, while other patients may
have their dose increased to a level that is toxic when they
actually begin taking it. Standardized and multidimensional
approaches to measuring adherence are needed to ensure
that patients receive optimal beneﬁts from the medication
while also minimizing risks to patients.
Overall, research indicates low and variable adherence
ratestodiﬀerent components of the SCD treatment regimen.
Studies identifying barriers to adherence have indicated
a clear link between adherence and poor clinical out-
comes in pediatric populations [25]. In pediatric SCD
samples, studies have identiﬁed the following as key bar-
riers: competing activities, health status, patient-provider
relationships, adverse clinical experiences, and forgetting
[26]. Other studies have identiﬁed sociocultural barriers to
adherence including developmental factors, transportation,
and health literacy [27–29]. Multicomponent, behavioral,
and educational interventions to promote adherence have
been found to be well-established pediatric treatments, [30,
31]; however, a recent study indicates that the quality of
the adherence assessment is one of the best predictors for
improving clinical outcomes [25]. Newer technologies (e.g.,
computer-based, text messaging) represent an opportunity
for developing high quality, standardized and cost-eﬀective
assessments of treatment adherence and clinical outcomes
such as patient experience of care (e.g., communication with
and responsiveness of staﬀ, quality of information received,
wait time, satisfaction, etc.), disease-speciﬁc outcomes (e.g.,
labs) and health-related quality of life [32]. These types
of approaches have been used eﬀectively in chronic illness
populations including adults with hypertension, diabetes
[33, 34], and pediatric asthma [35].
The current study represents a ﬁrst step in integrating
interactive web-based technologies in SCD clinical care. The
aims of the current study were to pilot an interactive family-
based web-based tool, the Take-Charge Program, to assess
adherence and clinical outcomes including: (1) patient HU
adherence,barrierstoHUadherence,andpotentialsolutions
to improve HU adherence; (2) patient clinic attendance
adherence, barriers to clinic attendance adherence, and
potential solutions to improve clinic attendance; and (3)
clinical outcomes (patient experience of care, sickle-related
outcomes hemoglobin level, ANC, MCV, and percent fetal
hemoglobin level for HU patients).
2.ParticipantsandMethods
Datapresentedinthispaperarefromthebaselineassessment
of a larger longitudinal study being conducted at a tertiary
urban pediatric medical center in the Midwest. Eligible
participantswerepatientsofacomprehensiveSCDclinic,age
6 to 21 years (and their caregivers), and prescribed hydrox-
yurea (HU) therapy or referred by clinic staﬀ for attendance
problems. Patients who had signiﬁcant health complications
(e.g., acute illness, recent stroke) that would interfere with
the completion of the study or signiﬁcant cognitive or
developmental disabilities were excluded due to the demand
on participants to understand questions in the assessment.
Of the 182 patients in the clinic, 98 were eligible based on the
above criteria. To date, 47 patients have been enrolled in the
study with 4 being withdrawn because they no longer met
criteria; thus, data will be presented on the 43 participants in
the sample. Potential participants were identiﬁed by the clin-
ical staﬀ and the research team conﬁrmed eligibility criteria.
All participants were approached during a scheduled clinic
visit. After obtaining consent, data collection proceeded at
that visit.
2.1. Measures. Patients and caregivers completed the follow-
ing measures.
2.1.1. Background Information Form. This form summarized
personal/family demographic information, including par-
ticipant school/vocational history, parent education, family
income, family transitions, and life events. In addition, self-
report of pain frequency and intensity, and hospital and
emergency room visits over the past year was collected for
comparison with data collected from the medical record
review.
2.1.2. Barriers to Care Questionnaire [36]. This validated and
reliable 40-item questionnaire measures parents’ report of
encounters or situations that may interfere with access to
care, use of care, the patient-physician experience, or adher-
ence with medical instructions. Barriers are conceptualized
as multidimensional and include pragmatics (logistics, cost),
expectations about care, health knowledge and beliefs,
marginalization and health care navigation skills.
2.1.3. The Take Charge Program (Web-Based Tool). Av o i c e -
automated interactive web-based assessment tool was devel-
oped based on questions from the Disease ManagementAnemia 3
Interview [37] and consultation from clinic staﬀ.C a r e g i v e r
and child dyads complete the tool which takes approxi-
mately 15–20 minutes. The measure included questions and
prompts that enabled patients and caregivers to identify
barriers to adherence to clinic attendance and HU from a
standard list [26, 37] and at least one strategy for improving
adherence. The voice-automation increased the validity as
literacy was not required to complete the measure. The
initial development of the Take-Charge Program has been
described elsewhere [38]. During the second phase of
development, patients and caregivers matched barriers and
potential solutions for HU. Cognitive interviewing was used
to ensure that questions were being understood as intended
[36, 38]. The web-based tool assessed clinic attendance,
hydroxyurea adherence, and patient experience of care. The
Clinic Attendance Module assessed self-reported adherence
to clinic appointments on a 10-point Likert-type scale
with 10 representing perfect adherence. The hydroxyurea
module assessed self-reported HU adherence on a 10-point
Likert-type scale with 10 representing perfect adherence.
Both modules also asked participants to select applicable
barriers and a potential solution to address these barriers.
The Patient Experience of Care Module, an adapted version
of Krahn et al.’s [39] questionnaire using a 4-point Likert
scale and 2 open-ended questions assessed (1) wait time in
clinic, (2) understanding of treatment recommendations by
healthcareteam,(3)timespentwithhealthcareteam,and(4)
helpfulness of web-based tool. Once participants identiﬁed
a potential solution to try, clinic staﬀ or a member of the
research team utilized a standardized problem-solving inter-
vention adapted from Behavioral Family Systems Therapy
[40]tohelpparticipantsdevelopaspeciﬁcplantoimplement
the solution.
2.1.4. Medical Record Review. Electronic medical records
were reviewed to conﬁrm participant’s type of SCD and
collect the following data: hemoglobin level, ANC, MCV,
percent fetal hemoglobin, clinic attendance, ER visits, and
hospitalizations. Information on the participant’s prescribed
treatment plan was also collected and veriﬁed with clinic
staﬀ.
2.2. Data Analysis. Data collected from the web-based tool
and electronic medical record (EMR) were integrated into
a single database. Descriptive statistics and frequencies were
utilized to summarize demographics, health characteristics,
health care utilization, self-reported adherence, barriers,
potential solutions, and patient experience of care. Pearson
product-moment correlation coeﬃcients were computed
to conduct exploratory analyses to assess the relationship
between adherence to clinic visits (e.g., self-reported barriers
on the Take-Charge Program, number of barriers), adher-
ence to HU (e.g., self-reported barriers on the Take-Charge
Program, number of barriers), demographics, patient expe-
rience of care and sickle cell related outcomes. All analyses
were conducted in IBM SPSS Statistics 19 (SPSS: An IBM
Company).
3. Results
3.1. Participants. Study participants included 43 youth with
SCD(M = 12.81+3.98years;39.5%Male;79.0%HbSS;9.3%
HbSC; 4.7% Hβ+Thal; 7.0% other) and their primary care-
givers(83.7%mothers;7.0%fathers;9.3%other).Additional
demographic characteristics are reported in Table 1. This
sample is representative of the total SCD clinic population,
with the exception of hemoglobin type (fewer participants
with HbSC) but is consistent with the fact that the majority
ofparticipantsinthestudywereonHUtherapy.Withrespect
to clinical characteristics, 62.2% of the sample reported
having six or less pain days in the past 12 months, and 61.5%
reported missing 6 days of school for pain in the past 12
months.Emergencyroom(ER)visitandhospitalizationdata
indicated that most participants had three or fewer ER visits
(95.1%) or hospitalizations (90.5%) in the past 12 months
(see Table 2).
3.2. Clinic Attendance. According to the data, approximately
half of participants (47.5%) indicate that they “always come”
when describing their clinic attendance over the previous
12 months. This self-reported adherence was similar to
data obtained from the EMR which indicated that 55%
of patients never missed an appointment during this same
period. Although about half of patients missed at least
one appointment, a higher percent (75%) understood that
their SCD providers recommended clinic appointments at
least twice a year, and participants attended 84.5% of all
scheduled appointments. Top-rated barriers on the Barriers
to Care Questionnaire (BCQ) were related to pragmatics
(i.e., logistics, cost) (M = 76.1; SD = 15.7) and health-
care navigation skills (M = 79.4, SD = 22.4). When
asked speciﬁcally about barriers to clinic attendance on the
Take-Charge Program, participants reported the following
barriers: transportation diﬃculties (22.5%), inability to take
oﬀ from work/school (17.5%), forgetting (10%), waiting
too long (7.5%), competing activities (e.g., sports; 5%),
feeling tired (5%); dislike of treatments (2.5%), feeling it
is unnecessary (2.5%), and other (10%). Other barriers
included getting appointment dates and times confused,
not having transportation vouchers/setup, and not having
appointments available at a time that works with the
family’s schedule. For potential solutions, 47.1% chose an
individualized solution; 29.4% reported that they would try
scheduling their appointment at a better/diﬀerent time; and
5.9% reported that they would try setting an alarm (e.g.,
phone).
Participants were asked to rate their adherence on a scale
of 0 to 10 with 10 being no problems with adherence. The
mean rating for the sample was 8.9/10 (N = 40; SD:2.1).
They were also asked to rate how many visits they miss
per year on average. The mean for missed visits was 1.0
(N = 40; SD = 1.4). Exploratory analyses showed that a
greater percentage of no shows over the 12 month period
prior to study enrollment was positively related to (1) more
self-reportedbarrierstoclinicattendanceontheTakeCharge
Program r = .550, n = 40, P<. 001; (2) the number of visits
required r = .455, n = 39, P<. 01; (3) age r = .317, n = 41,4 Anemia
Table 1: Patient demographics.
N (%) Mean (SD)
Hemoglobin type
HbSS 34 (79.0)
HbSC 4 (9.3)
Hb+Thal 2 (4.7)
Other 3 (7.0)
Gender
Male 17 (39.5)
Female 26 (60.5)
Age 12.81 (3.98)
Race
African-American 43 (100)
Grade in school, median 6th
Primary caregiver
Mother 36 (83.7)
Father 3 (7.0)
Other relative 4 (9.3)
Highest grade completed by caregiver
High school 15 (34.9)
Some college 14 (32.6)
College degree 13 (30.2)
Grad school 1 (2.3)
Family income
< $10,000 14 (33.3)
$10,000–20,000 4 (9.5)
$21,000–30,000 6 (14.3)
$31,000–50,000 5 (11.9)
> $51,000 13 (31.0)
P<. 05; and (4) marginally related to satisfaction with clinic
visits r = .323, n = 40, P<. 052.
3.3. Hydroxyurea Adherence. While less than a third of
participants (26.7% saying “yes”) reported that they “always
took their HU,” overall, participants rated themselves as
an 8.8 on a 10-point scale for “how often do they take
their medicines?” which converts to 88%. When asked about
missing doses, participants reported that they missed an
average of 1.3 doses of HU per week. Participants reported
the following barriers to HU on the Take-Charge Program:
forgetting (56.7%), not having the medication with me
(26.7%), the medications running out (23.3%), yucky taste
or smell (12.5%), upset stomach (12.5%), and being not
sure why I take it (3.1%). Other barriers reported included
not wanting to stop what the patient is doing to take
medication and taking too many medications. For potential
solutions, 20% chose to try putting the medication next
to something they do every day (e.g., toothbrush, breakfast
table); 15% chose to use an alarm clock or cell phone
alarm; 15% chose to use a pill box; and 15% chose to use
a calendar. Additional solutions selected were reminder calls,
and coordinating better with child/caregiver. Also, clinic staﬀ
rated that approximately 40% of participants were adherent
to medications based on clinical data but staﬀ felt that the
clinicaldataoftheother60%indicatednonadherenceorthat
further monitoring was needed. Number of missed doses of
HU during the previous two weeks was related to age, with
older age being related to greater nonadherence r = .372,
n = 31, P = .036 and greater number of barriers reported on
the Take-Charge Program r = .421, n = 31, P = .023.
3.4. Clinic Integration. Nearly all participants and their
parents (41/43) completed the web-based assessment tool
while waiting to see the care team for their appointment.
The tool collected accurate and complete data with minimal
missing data (3 participants due to technical errors). The
majority of participants (64.9%) rated the web-based tool as
very helpfulandanother twenty-ﬁvepercent(24.3%) rated it
as a little helpful.
3.5. Clinical Outcomes
Patient Experience of Care. The majority of patients (82%)
reported a reasonable wait time (43% not at all; 29% short
time) and only 18% reported that their wait time for the visitAnemia 5
Table 2: Patient clinical characteristics.
N (%) Range
Pain days in past 12 months∗ 0–45
0 days 5 (11.6)
1-2 days 9 (20.9)
3–5 days 6 (14.0)
6–10 days 7 (16.3)
>10 days 16 (37.2)
Missed school days due to pain in past 12 months+∗ 0–45
0 days 8 (19.0)
1-2 days 6 (14.3)
3–5 days 7 (16.7)
6–10 days 9 (21.4)
>10 days 12 (28.6)
Hospitalizations in past 12 months+∗ 0–20
0 15 (35.7)
1-2 19 (45.2)
3 5 (11.9)
41 ( 2 . 4 )
51 ( 2 . 4 )
20 1 (2.4)
ER visits in past 12 months+∗ 0–20
0 8 (19.0)
1-2 27 (64.3)
3 5 (11.9)
81 ( 2 . 4 )
20 1 (2.4)
∗n = 37
+∗n = 42
was too long. With respect to the visit itself, approximately
79.5% of participants reported that they were satisﬁed with
the amount of time the medical team spent with them
during their visit. In addition, the majority of participants
(82.1%) reported that what the medical team shared with
themwasveryhelpful.Speciﬁcally,participantsreportedthat
the medical information was helpful (16%), and they found
discussionsaboutthetreatmentplan(e.g.,discussionaround
medicine dosage and test results; about steps she needs to
taketostayhealthy)verybeneﬁcial(12%).Someparticipants
(38%) also reported that other things made the visit positive
(e.g., toys, movies).
Sickle Cell-Related Lab Values. Lab values from the date of
enrollment into the study (or within 30 days of enrollment)
were obtained from an electronic portal that pulls data from
the electronic medical record system. The mean hemoglobin
level for participants was 9.7 (N = 39; SD = 1.28). For
those participants on HU therapy, the mean percent fetal
hemoglobin was 23.1 (N = 26; SD = 15.6), the MCV was
98.0 (N = 28; SD = 13.9), and the ANC was 4.2 (N = 27;
SD = 2.44). There was not a signiﬁcant relationship between
lab values and patient satisfaction with the amount of time
spentwiththemedicalteamorthehelpfulnessofthemedical
information shared during the visit.
4. Discussion
This study highlights the potential to eﬃciently integrate
interactive web-based technology in a clinic-based setting
to assess treatment adherence, patient experience of care,
and disease-speciﬁc outcomes in pediatric SCD. This study
is signiﬁcant as it piloted an innovative and high quality
assessment process for capturing adherence data, including
the barriers to adherence and potential solutions for address-
ing these barriers. The data from the tool showed a number
of interesting trends. First, the tool proved to be a useful
means for collecting data to understand adherence to clinic
visits. Self-reported adherence to clinic visits was consistent
with data from patients’ EMR as both sources revealed a 12-
month clinic attendance adherence rate (“always coming”
and“attendingallvisits”)ofapproximately50%.Itshouldbe
notedthatthenumberofmissedvisitsandadherencemaybe
relative given that patients had 2 to 17 visits scheduled over
the course of the year based on the complexity of treatments
and disease-related complications (e.g., hospital discharge
followup). Taken together, these ﬁndings suggest that nearly6 Anemia
85% of all scheduled clinic visits were attended by partici-
pants in this study. Understanding barriers to nonadherence
was also important, especially given that adherence to clinic
visits does not take into account cancellations, same day
cancellations or rescheduled visits as a nonattended visit.
Finally, data from the Take-Charge Program was integrated
with patients’ EMR data providing a wealth of data to inform
clinical practice in “real time.”
The barriers to clinic attendance endorsed by partic-
ipants were multifaceted and included logistical (trans-
portation, getting oﬀ work), health care navigation skills
(usingcalendarstomanagemultipleappointmentsandmed-
ications), socioeconomic (lack of insurance), and disease-
related barriers (did not feel well). BCQ mean scores for
this sample were consistent with mean scores for other
pediatric populations with similar challenges (e.g., asthma,
children with special health care needs) [36, 41]. Participants
also identiﬁed potential solutions for improving adherence
and attendance (which is the basis for a larger longitudinal
intervention study). Additional potential risk factors for
no-shows emerged from exploratory analysis of the data
which found that nonadherence to clinic visits increased
with age, more required visits, and self-reported barriers
to attendance. These ﬁndings, though preliminary, further
highlight the richness of the data and provide meaningful
trends and a basis for prioritizing patients who may be
in need of additional clinical supports to ensure patient
engagement and attendance.
The Take-Charge tool was also piloted to better under-
stand the subset of patients on HU (74% of the sample).
Anecdotally, nonadherence to HU is cited as a problem
for many children and adolescents with SCD although
developmentally-appropriate approaches for children and
adolescents are very limited. The ﬁndings support that the
Take-Charge tool was useful for assessing relevant informa-
tion from participants on HU related to their perceptions
of how they are to be taking their medications, concerns
about side-eﬀects and other barriers. Data from the tool
highlighted that approaches to working with patients around
medication management will need to address organizational
issues [18, 19] such as helping patients and parents use cal-
endars, phone alarms, and emerging innovative technologies
(e.g., pill cases that glow in the dark and beep) to reduce the
potential for “forgetting” to take medications, getting them
reﬁlled, and packing them when away from home.
Qualitative data from participants further highlight the
importance of implementing family-based strategies and
the need to tailor them appropriately to individual needs.
Medication side-eﬀects (e.g., taste, smell, upset stomach)
and lack of awareness (i.e., to address patients who are not
sure why they are taking medication) are other important
barriers to address. Interestingly, some of the reasons
that are commonly considered for nonadherence (e.g., the
probability for loss of hair, stigma, fear of blood draws, and
that the medicine would not make a diﬀerence) were not
endorsed by these participants but still may be important for
patients who do not agree to try the medication or who show
early signs of nonadherence. Several participants noted that
transportation and lack of insurance were barriers not only
to clinic attendance, but also to HU adherence, highlighting
the pervasiveness of income and access to health care on
adherence. The barriers that are assessed in the tool appear
to have some clinical utility as more barriers were related
to a higher number of missed doses of medicine during
the previous two weeks prior to the study. This study also
supports previous research which suggests that age should
also be considered as a target in the clinical evaluation, given
the potential for nonadherence to medication increased
with age [10, 34]. Data support the potential for the tool
to reliably assess adherence and other health utilization
outcomes while fostering individualized and family-based
solutions for addressing barriers to adherence to clinic visits
and medication. Patient experience of care data on the
clinical integration of the tool showed positive trends with at
least 90% of participants endorsing satisfaction/helpfulness
of the tool. It was positive that satisfaction with the clinic
visit was also not compromised with >90% also endorsing
satisfaction with the clinic visit.
The limitations of the study should be noted. First, given
the pilot/feasibility nature of the study, only patients who
were engaged in our clinic were included in the study. It
will be important in future clinical research to understand
and address the barriers of patients (perhaps via the web
or other engaging methods) who have lost contact or who
are unable to attend clinic because of barriers and risks to
determineifmoresigniﬁcantinterventionisneeded.Second,
the study included a range of participants across a broad
developmental level. In addition, since this was a family-
based assessment and intervention study, individual reports
ofbarriersforpatientsandcaregiverswerenotcollected.This
limitation should be overcome in future studies by insuring
that older patients identify individual barriers to treatment
adherence. Third, patients were diverse in income, disease
severity, and other factors. Replicating this study with a
larger sample to better understand adherence within devel-
opmental and disease-related subgroups will be important.
Fourth, data collection from the EMR was a challenge in
this study as corresponding lab values were not available
for all study visits. It will be essential to better coordinate
lab draws and study visits and to ensure study funds to
pay for corresponding labs so that data can be tracked over
time. Finally, the data reported here are cross-sectional and
some are self-reported in nature. Future research is needed
to monitor clinical outcome data longitudinally and to assess
the relationship between adherence and clinical outcomes
over time.
An e x ts t e pi na d v a n c i n go u rr e s e a r c hi st or e ﬁ n e
the tool. There were a number of “other” responses that
received a high endorsement which justify some additional
revision of existing screens to include additional response
options. While this program has the potential to be used
as a tool to help improve adherence and clinical outcomes
during follow-up visits, a goal and a challenge will be to
maintain high patient satisfaction with the program. As the
program becomes further standardized, another goal will be
to streamline the clinic integration process and to pilot it
in other SCD clinic settings. In spite of these limitations
the study’s overall goal was met which was to integrate theAnemia 7
web-based tool within a clinic-based setting (rather than in
a nonclinical research setting) and to assess adherence and
clinical outcomes for pediatric patients with SCD.
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